Analyst Ratings For Cytori Therapeutics (NASDAQ:CYTX)
Today, Laidlaw reiterated its Buy rating on Cytori Therapeutics (NASDAQ:CYTX) with a price target of $1.65.
Some recent analyst ratings include
- 2/22/2018-Laidlaw Reiterated Rating of Buy .
- 11/7/2017-B. Riley Reiterated Rating of Hold.
- 6/28/2016-Roth Capital Reiterated Rating of Buy.
Recent Insider Trading Activity For Cytori Therapeutics (NASDAQ:CYTX)
Cytori Therapeutics (NASDAQ:CYTX) has insider ownership of 1.90% and institutional ownership of 10.41%.
- On 2/13/2018 Ag Postfinance, Major Shareholder, sold 286,982 with an average share price of $0.31 per share and the total transaction amounting to $88,964.42.
- On 2/9/2018 Ag Postfinance, Major Shareholder, sold 236,155 with an average share price of $0.34 per share and the total transaction amounting to $80,292.70.
- On 1/11/2018 Bank Sa Swissquote, Major Shareholder, sold 72,630 with an average share price of $0.34 per share and the total transaction amounting to $24,694.20.
- On 1/9/2018 Bank Sa Swissquote, Major Shareholder, sold 100,000 with an average share price of $0.38 per share and the total transaction amounting to $38,000.00.
- On 8/10/2016 John David Harris, VP, bought 2,500 with an average share price of $2.03 per share and the total transaction amounting to $5,075.00.
- On 6/14/2016 Gail K Naughton, Director, bought 1,000 with an average share price of $2.10 per share and the total transaction amounting to $2,100.00.
- On 5/13/2016 John David Harris, VP, bought 2,000 with an average share price of $2.71 per share and the total transaction amounting to $5,420.00.
Recent Trading Activity for Cytori Therapeutics (NASDAQ:CYTX)
Shares of Cytori Therapeutics closed the previous trading session at 0.36 up +0.02 6.02% with 0.36739999055862427 shares trading hands.